Tag: vaccine
1. Out of 5,150,310 individuals in England that received two COVID-19 vaccine doses, 81 patients passed away from COVID-19 and 71 were admitted to hospital for COVID-19, at least 14 days after their 2nd dose.
2. Factors that increased risk the most for a serious COVID-19 outcome in partially or fully vaccinated...
1. Approximately 8.5 million children were estimated to have missed DTP3 and MCV1 vaccinations in 2020 due to the global pandemic.
2. The largest disruptions were seen in April and May 2020, with some countries recovering to annual targets by the end of 2020.
Evidence Rating Level: 3 (Average)
Study Rundown: The...
1. In a cohort of pregnant women in the United Kingdom, COVID-19 vaccines did not alter perinatal outcomes.
Evidence Rating Level: 2 (Good)
The Coronavirus disease 2019 (COVID-19) has caused significant morbidity and mortality across the world. Mass vaccination has been a key strategy used by countries to help control the...
1. Allergic reactions and anaphylaxis following first dose of mRNA COVID-19 vaccines were not associated with immediate, adverse reactions following second dose.
2. Antihistamine premedication may further mitigate risk of allergic reactions.
Evidence Rating Level: 2 (Good)
After several months of messenger RNA (mRNA) COVID-19 vaccines being available in the US, allergic...
1. CoronaVac, an inactivated SARS-CoV-2 vaccine, offers reduced but adequate short-term immunogenicity among people with autoimmune rheumatic diseases.
Evidence Rating Level: 2 (Good)
In the context of an ongoing COVID-19 pandemic, several vaccines have been approved for emergency use in the hope of reducing the spread of infection. Several countries have...
1. A plant-derived, virus-like particle displays the SARS-CoV-2 spike glycoprotein and appears to be a promising candidate for a vaccine.
2. Adverse outcomes were mild-to-moderate, transient, and dependent on adjuvant.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Available vaccines for COVID-19 are proving to be effective and safe. However, the demand for...
1. Vaccine efficacy at 6 months for R21/MM was 74% in group 1 and 77% in group 2.
2. R21/MM showed high malaria-specific antibody titers at 28 days after the third vaccination, which doubled with higher adjuvant doses.
Evidence Rating Level: 1 (Excellent)
Study Rundown: The development of an effective vaccine against Plasmodium falciparum – the major...
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their second vaccine dose.
2. Substantial and consistent declines in COVID-19 incidence corresponded to greater vaccine coverage.
Evidence Rating Level: 2 (Good)
Study Rundown: Beyond clinical trials, there is growing evidence of the...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort.
2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose.
Evidence Rating Level: 2 (Good)
Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19 vaccines have been...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort.
2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose.
Evidence Rating Level: 2 (Good)
Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19...